Soleno Therapeutics Investors Face May 5 Deadline to Seek Lead Role in Securities Class Action

Overview

• Investor notices from Hagens Berman, Rosen Law Firm, and Kahn Swick & Foti urge shareholders to file for lead‑plaintiff status by May 5, 2026.
• The case, City of Pontiac Police & Fire Ret. Sys. v. Soleno Therapeutics, Inc. (No. 26‑cv‑01979), was filed in the Northern District of California and covers purchases from March 26, 2025 through November 4, 2025.
• Plaintiffs allege Soleno misled the market about DCCR’s safety and demand, citing claims of excess fluid retention and possible heart issues in children, plus inflated launch “start form” counts.
• The complaint points to an August 2025 short‑seller report and to Soleno’s November 2025 update acknowledging fewer patient starts and more discontinuations, after which the stock fell about 27% in one day.
• The firms are also seeking whistleblowers under the SEC program, while reminding investors that no class has been certified and that serving as lead plaintiff is optional for sharing in any potential recovery.